Back to Search
Start Over
Efficacy of immune checkpoint inhibitors according to PD‐L1 tumor proportion scores in non‐small cell lung cancer
- Source :
- Thoracic Cancer, Vol 11, Iss 2, Pp 408-414 (2020), Thoracic Cancer
- Publication Year :
- 2019
- Publisher :
- Wiley, 2019.
-
Abstract
- Background We correlated the tumor proportion score (TPS) of programmed cell death ligand 1 (PD‐L1, SP263 or 22C3) expression with the disease control rate (DCR, partial remission and stable disease), and progression free survival (PFS) after nivolumab or pembrolizumab treatment. Methods A total of 70 case records (55 males, 15 females) of patients with non‐small cell lung cancer (NSCLC, 46 adenocarcinoma, 22 squamous cell carcinoma, and two others) were reviewed. The PD‐L1 expressions were divided into High (SP263 ≥ 30%, 22C3 ≥ 80%) and Low groups (SP263
- Subjects :
- Male
non‐small cell lung cancer
0301 basic medicine
Pulmonary and Respiratory Medicine
Lung Neoplasms
Immune checkpoint inhibitors
Adenocarcinoma of Lung
Pembrolizumab
lcsh:RC254-282
B7-H1 Antigen
Programmed cell death ligand 1
03 medical and health sciences
0302 clinical medicine
Stable Disease
Carcinoma, Non-Small-Cell Lung
PD-L1
Biomarkers, Tumor
Humans
Medicine
Progression-free survival
Lung cancer
Immune Checkpoint Inhibitors
Aged
Retrospective Studies
biology
business.industry
programmed cell death ligand 1
Original Articles
General Medicine
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Survival Rate
Nivolumab
030104 developmental biology
Oncology
030220 oncology & carcinogenesis
Carcinoma, Squamous Cell
Cancer research
biology.protein
Female
Original Article
pembrolizumab
business
Follow-Up Studies
Subjects
Details
- ISSN :
- 17597714 and 17597706
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Thoracic Cancer
- Accession number :
- edsair.doi.dedup.....6e5bedeabba04d239dee7771eb846385